Related Experiment Video
Updated: Oct 23, 2025
07:01
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
9.2K
Pharmacotherapy for Seizures in Tuberous Sclerosis Complex
Rima Nabbout1,2, Mathieu Kuchenbuch3,4, Catherine Chiron3,5
1Reference Centre for Rare Epilepsies, Department of Pediatric Neurology, Necker Enfants Malades University Hospital, APHP, Université de Paris, 149 rue de Sèvres, 75015, Paris, France. rima.nabbout@aphp.fr.
CNS Drugs
|August 21, 2021
Summary
Epilepsy significantly impacts tuberous sclerosis complex (TSC) patients. Proactive strategies, including vigabatrin and mTOR inhibitors, show promise in preventing seizures and improving outcomes.
Area of Science:
- Neurology
- Genetics
- Pediatrics
Background:
- Epilepsy is a primary symptom of tuberous sclerosis complex (TSC), leading to significant morbidity.
- Individuals with TSC experience diverse seizure types and epilepsy syndromes, impacting quality of life and cognitive development.
Purpose of the Study:
- To review current understanding and management strategies for epilepsy in TSC.
- To highlight the shift towards proactive and personalized epilepsy treatment in TSC.
Main Methods:
- Literature review of epilepsy mechanisms and treatments in TSC.
- Analysis of current and emerging therapeutic approaches, including vigabatrin and mTOR inhibitors.
Main Results:
- Focal epilepsy is most common in TSC, including infantile spasms syndrome and Lennox-Gastaut syndrome.
- A proactive approach, including vigabatrin, can predict, prevent, and delay seizure onset in TSC-related epilepsy.
- Mechanistic therapies, such as mTOR inhibitors, offer personalized treatment options.
Conclusions:
- Early screening and management of epilepsy in TSC are crucial for limiting consequences.
- The paradigm is shifting from reactive to proactive and personalized epilepsy care in TSC.
- Long-term effects of these interventions on cognitive and psychiatric outcomes require further investigation.
Related Concept Videos
01:08Antiepileptic Drugs: Sodium Channel Blockers
1.1K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.1K
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
823
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
823
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
540
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
540
01:24Epilepsy and Seizures: Overview
469
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
469
01:14Antiepileptic Drugs: Glutamate Antagonists
607
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
607
01:17Antiepileptic Drugs: Calcium Channel Blockers
776
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
776